All Programs

Use the tool below to view all available Global Neurology Academy Series

Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Project Oncology®
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
- Alexandria May, PharmD, BCPS
- Angela Waanders, MD, MPH, MS
- Ashley S. Margol, MD, MS
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
Clinician's Roundtable
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
- Charles Turck, PharmD, BCPS, BCCCP
- Caterina Garone, MD, PhD
Individualizing gMG Treatment: Defining Success With Each Patient
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiers
Individualizing gMG Treatment: Defining Success With Each Patient
- Omar Sinno, MD
Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Clinician's Roundtable
Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
- Stephen Wong, PhD
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
CME/CE
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
0.25 credits
- Christoph U. Correll, MD
- Jonathan M. Meyer
0.25 credits
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
CME/CE
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
0.50 credits
- Neelam Goyal, MD
- Christyn Edmundson, MD
0.50 credits
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiers
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
NeuroFrontiers
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
- Ryan Quigley
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
Global Neurology Academy
Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care
- Vikram V. Bhise, MD
Evolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
Evolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
Global Neurology Academy
Evolving Diagnostic and Prognostic Strategies in Multiple Sclerosis Care
- Ashley Baker, MSN, PMHNP
- Jay Avasarala, MD, PhD
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
NeuroFrontiers
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
- Michael Levy, MD, PhD
From Resistance to Response: Evolving Strategies in MDD Management
From Resistance to Response: Evolving Strategies in MDD Management
CME/CE Broadcast Replay
From Resistance to Response: Evolving Strategies in MDD Management
1.00 credit
- Joseph F. Goldberg, MD
1.00 credit
Modern MS Management: Leveraging Technology to Support Brain Health
Modern MS Management: Leveraging Technology to Support Brain Health
Global Neurology Academy
Modern MS Management: Leveraging Technology to Support Brain Health
- Victoria Leavitt, PhD
- Gates B. Colbert, MD
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
NeuroFrontiers
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
NeuroFrontiers
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
- Marc Haut, PhD
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
Global Neurology Academy
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay

All Programs

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

All Programs

Popular

Title

Share on ReachMD